Joshi Alumkal

Stories

Researchers find drug combo that slows treatment-resistant prostate cancer

As of September 2026: Leading the research team behind the JCI Insight study

Some prostate cancer tumors survive treatment by changing what they are—losing glandular identity and adopting stem-cell-like traits, a process called transdifferentiation. A University of Michigan team showed in JCI Insight that combining two drug classes reverses many of those changes and sharply slows tumor growth in mice.

Updated Sep 8

Notable Quotes

We saw that there are two sides to this transition: loss of glandular genes and activation of cell programs that cause the identity to switch into stem cells.

from Researchers find drug combo that slows treatment-resistant prostate cancer · Updated Sep 8

Preventing the emergence of transdifferentiation would be key to patient survival.

from Researchers find drug combo that slows treatment-resistant prostate cancer · Updated Sep 8